Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kazia Therapeutics Ltd ADR (KZIA)

Kazia Therapeutics Ltd ADR (KZIA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,262
  • Shares Outstanding, K 13,201
  • Annual Sales, $ 11,380 K
  • Annual Income, $ -6,290 K
  • 60-Month Beta 2.39
  • Price/Sales 6.80
  • Price/Cash Flow N/A
  • Price/Book 4.32
Trade KZIA with:

Options Overview Details

View History
  • Implied Volatility 151.74% ( +17.89%)
  • Historical Volatility 58.61%
  • IV Percentile 81%
  • IV Rank 34.90%
  • IV High 269.31% on 05/25/22
  • IV Low 88.71% on 10/22/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,358
  • Open Int (30-Day) 1,505

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.01 +21.36%
on 05/12/22
6.97 -12.77%
on 05/23/22
-0.73 (-10.72%)
since 04/27/22
3-Month
5.01 +21.36%
on 05/12/22
8.61 -29.38%
on 04/06/22
-0.67 (-9.93%)
since 02/25/22
52-Week
5.01 +21.36%
on 05/12/22
12.28 -50.49%
on 11/03/21
-3.34 (-35.46%)
since 05/27/21

Most Recent Stories

More News
Kazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer

LONDON, UK / ACCESSWIRE / May 26, 2022 / In light of the positive newsflow from Kazia's efforts in addressing adult brain cancer, management is leveraging its niche expertise and experience to address...

KZIA : 6.08 (+4.11%)
Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts

LONDON, UK / ACCESSWIRE / March 30, 2022 / Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential regulatory...

KZIA : 6.08 (+4.11%)
Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4

LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly diagnosed...

KZIA : 6.08 (+4.11%)
Proactive news headlines including Buru Energy, Meteoric Resources, MGC Pharmaceuticals and Vango Mining

Sydney, June 15, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

BRNGF : 0.1420 (+4.80%)
BUD : 56.65 (+0.30%)
MEI : 45.34 (+2.65%)
RNF : 11.41 (-1.89%)
MXC : 19.26 (+8.20%)
MXC.LN : 1.100 (unch)
MGCLF : 0.0145 (-6.45%)
EMD : 9.83 (+0.31%)
AXE : 97.85 (-0.02%)
ARRXF : 0.5125 (+2.50%)
KZIA : 6.08 (+4.11%)
Proactive news headlines including Okapi Resources, Global Energy Ventures, Kazia Therapeutics and QMines

Sydney, June 07, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

KZIA : 6.08 (+4.11%)
PGM : 47.08 (+11.91%)
PTNUF : 0.0219 (-52.18%)
TMRR : 1.6700 (+0.60%)
TMRFF : 0.0539 (+3.85%)
FYIRF : 0.1751 (-11.83%)
EMD : 9.83 (+0.31%)
Proactive news headlines including Chase Mining Corporation, Red River Resources, Aurumin and Kazia Therapeutics

Sydney, April 26, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

KZIA : 6.08 (+4.11%)
EVT : 25.63 (+2.36%)
PAR : 38.85 (+4.80%)
FEX : 85.41 (+2.15%)
MZZ : 17.45 (-4.33%)
Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis

LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for €1m...

KZIA : 6.08 (+4.11%)
Proactive news headlines including Queensland Pacific Metals, Moho Resources, Kazia Therapeutics and Perseus Mining

Sydney, April 20, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

MOH : 305.08 (+2.03%)
KZIA : 6.08 (+4.11%)
EVT : 25.63 (+2.36%)
PRU : 106.27 (+1.64%)
PMNXF : 1.3300 (-0.75%)
KWR : 155.10 (+3.75%)
Proactive news headlines including Australian Potash, Jindalee Resources, Kazia Therapeutics and Latin Resources

Sydney, April 09, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

APC : 72.77 (+0.78%)
KZIA : 6.08 (+4.11%)
ASM : 0.7199 (+3.58%)
ASMMF : 3.7471 (-1.13%)
Kazia Therapeutics (KZIA): Paxalisib Chinese Rights Licensed

LONDON, UK / ACCESSWIRE / March 30, 2021 / Kazia (NASDAQ:KZIA) has announced it has signed an agreement for the Greater China rights to paxalisib with Simcere Pharmaceuticals. The deal includes an US$11m...

KZIA : 6.08 (+4.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being...

See More

Key Turning Points

3rd Resistance Point 6.53
2nd Resistance Point 6.36
1st Resistance Point 6.22
Last Price 6.08
1st Support Level 5.91
2nd Support Level 5.75
3rd Support Level 5.61

See More

52-Week High 12.28
Fibonacci 61.8% 9.50
Fibonacci 50% 8.65
Fibonacci 38.2% 7.79
Last Price 6.08
52-Week Low 5.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar